Core Insights - NeoGenomics reported a 10% increase in full-year revenue to $727 million, with clinical revenue growing 15% [1] - The company successfully resolved RaDaR ST patent litigation, enhancing its product offerings [1] Financial Performance - Fourth quarter consolidated revenue rose 11% to $190 million, while full-year consolidated revenue increased 10% to $727 million [1] - The net loss for the fourth quarter decreased by 36% to $10 million, but the full-year net loss increased by 37% to $108 million [1] - Adjusted EBITDA for the fourth quarter was positive at $13 million, a 13% increase, and for the full year, it rose 9% to $43 million [1] Growth Drivers - The company experienced a 23% growth in Next-Generation Sequencing (NGS) in Q4 and 22% for the full year, outpacing market growth [1] - The upcoming clinical launch of the RaDaR ST MRD assay is expected to tap into the $20+ billion molecular residual disease monitoring market [1] Operational Metrics - Average revenue per clinical test increased by 5% to $488, with a 7% growth excluding Pathline tests [1] - Consolidated gross profit for Q4 was $83 million, an 8% increase, leading to a gross profit margin of 43.8% [1] Future Guidance - For FY 2026, the company projects consolidated revenue between $793 million and $801 million, representing a 9% to 10% year-over-year increase [1] - The anticipated net loss for 2026 is expected to range from $63 million to $50 million, a significant improvement from 2025 [1]